We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    RGX-314
Previous Study | Return to List | Next Study

RGX-314 Gene Therapy for Neovascular AMD Trial

This study is currently recruiting participants.
Verified August 2017 by Regenxbio Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03066258
First Posted: February 28, 2017
Last Update Posted: August 3, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Regenxbio Inc.
  Purpose
Excessive vascular endothelial growth factor (VEGF) plays a key part in promoting neovascularization and edema in neovascular (wet) age-related macular degeneration (nAMD). VEGF inhibitors (anti-VEGF), including ranibizumab (LUCENTIS®, Genentech) and aflibercept (EYLEA®, Regeneron), have been shown to be safe and effective for treating nAMD and have demonstrated improvement in vision. However, anti-VEGF therapy is administered frequently via intravitreal injection and can be a significant burden to the patients. RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein. The long-term, stable delivery of this therapeutic protein following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment burden of currently available therapies while maintaining vision with a favorable benefit:risk profile.

Condition Intervention Phase
Neovascular Age-related Macular Degeneration Wet Age-related Macular Degeneration Biological: RGX-314 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
dose escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)

Resource links provided by NLM:


Further study details as provided by Regenxbio Inc.:

Primary Outcome Measures:
  • Safety (incidence of ocular and non-ocular AEs and SAEs) [ Time Frame: 26 weeks ]
    incidence of ocular and non-ocular AEs and SAEs


Secondary Outcome Measures:
  • Safety (incidence of ocular and non-ocular AEs and SAEs) [ Time Frame: 106 weeks ]
    incidence of ocular and non-ocular AEs and SAEs

  • Change in best corrected visual acuity [ Time Frame: 106 weeks ]
    BCVA

  • Change in central retinal thickness [ Time Frame: 106 weeks ]
    CRT as measured by SD-OCT

  • Rescue injections (Mean number of rescue injections) [ Time Frame: 106 weeks ]
    Mean number of rescue injections

  • Mean change in area of CNV [ Time Frame: 106 weeks ]
    Area of CNV and leakage measured by FA


Estimated Enrollment: 18
Actual Study Start Date: March 31, 2017
Estimated Study Completion Date: February 2020
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dose 1
3E9 GC of RGX-314
Biological: RGX-314
RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
Experimental: Dose 2
1E10 GC of RGX-314
Biological: RGX-314
RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
Experimental: Dose 3
6E10 GC of RGX-314
Biological: RGX-314
RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein

Detailed Description:
This Phase I, open-label, multiple-cohort, dose-escalation study is designed to evaluate the safety and tolerability of RGX-314 gene therapy in subjects with previously treated nAMD. Three doses will be studied in approximately 18 subjects. Subjects who meet the inclusion/exclusion criteria and have an anatomic response to an initial anti VEGF injection will receive a single dose of RGX-314 administered by subretinal delivery. RGX-314 uses an AAV8 vector that contains a gene that encodes for a monoclonal antibody fragment which binds to and neutralizes VEGF activity. Safety will be the primary focus for the initial 24 weeks after RGX-314 administration (primary study period). Following completion of the primary study period, subjects will continue to be assessed until 104 weeks following treatment with RGX-314.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients ≥ 50 years with a diagnosis of subfoveal CNV secondary to AMD in the study eye receiving prior intravitreal anti-VEGF therapy.
  2. BCVA between ≤20/100 and ≥20/400 (≤53 and ≥19 Early Treatment Diabetic Retinopathy Study [ETDRS] letters) for the first patient in each cohort followed by BCVA between ≤20/63 and ≥20/400 (≤63 and ≥19 ETDRS letters) for the rest of the cohort.
  3. History of need for and response to anti-VEGF.therapy.
  4. Response to anti-VEGF at trial entry (assessed by SD-OCT at week 1)
  5. Must be pseudophakic (status post cataract surgery) in the study eye.
  6. AST/ALT < 2.5 × ULN; TB < 1.5 × ULN; PT < 1.5 × ULN; Hb > 10 g/dL (males) and > 9 g/dL (females); Platelets > 100 × 10^3/µL; eGFR > 30 mL/min/1.73 m^2
  7. Must be willing and able to provide written, signed informed consent.

Exclusion Criteria:

  1. CNV or macular edema in the study eye secondary to any causes other than AMD.
  2. Any condition preventing visual acuity improvement in the study eye, eg, fibrosis, atrophy, or retinal epithelial tear in the center of the fovea.
  3. Active or history of retinal detachment in the study eye.
  4. Advanced glaucoma in the study eye.
  5. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational product, other than anti-VEGF therapy, in the 6 months prior to screening.
  6. Presence of an implant in the study eye at screening (excluding intraocular lens).
  7. Myocardial infarction, cerebrovascular accident, or transient ischemic attacks within the past 6 months.
  8. Uncontrolled hypertension (systolic blood pressure [BP] >180 mmHg, diastolic BP >100 mmHg) despite maximal medical treatment.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03066258


Contacts
Contact: Rickey Reinhardt, MD, PhD 2405528181 RGX-314.ClinOps@regenxbio.com

Locations
United States, Maryland
Baltimore location Recruiting
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Boston location Recruiting
Boston, Massachusetts, United States, 02114
United States, Pennsylvania
Philadelphia location 1 Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Philadelphia location 2 Recruiting
Philadelphia, Pennsylvania, United States, 19107
United States, Tennessee
Memphis location Recruiting
Germantown, Tennessee, United States, 38138
United States, Texas
Houston location Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
Regenxbio Inc.
Investigators
Principal Investigator: Jeffrey Heier, MD Ophthalmic Consultants of Boston
  More Information

Responsible Party: Regenxbio Inc.
ClinicalTrials.gov Identifier: NCT03066258     History of Changes
Other Study ID Numbers: RGX-314-001
First Submitted: February 17, 2017
First Posted: February 28, 2017
Last Update Posted: August 3, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Regenxbio Inc.:
nAMD
wet AMD
gene therapy

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases